Table 2.
ORs for severe HFMD
| Risk factors | Unadjusted OR (95 % CI) |
AdjustedaOR (95 % CI) |
|---|---|---|
| Gender | 0.936 (0.535-1.637) | 1.105 (0.442–2.759) |
| Age | 0.828 (0.441–1.555) | 2.070 (0.692–6.815) |
| EV71-positivity | 9.906 (4.807–20.413)*** | 19.944 (6.492–61.271)*** |
| Peripheral WBC count >15 × 109/L |
4.926 (2.442–9.938)*** | 3.428 (1.186–9.914)* |
| Fasting glucose >8.3 mmol/L |
81.727 (11.045–604.760)*** | 19.428 (2.236–168.784)** |
| PCT >0.1 ng/mL | 3.737 (2.061–6.777)*** | 9.084 (3.462–23.837)*** |
| NT-proBNP > 125 pg/mL | 11.939 (5.205–27.383)*** | 16.649 (4.731–58.585)*** |
HFMD hand, foot, and mouth disease, EV71 enterovirus 71, PCT procalcitonin, NT-proBNP N-terminal of the prohormone brain natriuretic peptide
CI Confidence interval, OR odds ratio. OR was calculated using the mild children as a reference group
aIn multivariate logistic regression model (n = 216), we controlled for age, gender, EV71-seropositivity, WBC, fasting glucose, CK, LDH, PCT and NT-proBNP. After adjusting for potential confounding factors, there was significant difference in EV71 infection, peripheral WBC count, fasting blood glucose, PCT and plasma NT-proBNP levels
*P <0.05, **P <0.01, ***P <0.001